REFERENCES
- Robertson KR, Smurzynski M, Parsons TD, et al. The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS. 2007;21:1915–21.
- Sevigny JJ, Albert SM, McDermott MP, et al. Evaluation of HIV RNA and markers of immune activation as predictors of HIV-associated dementia. Neurology. 2004;63:2084–2090.
- Heaton RK, Clifford DB, Franklin DR Jr, et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology. 2010;75:2087–2096.
- Cysique LA, Brew BJ. Prevalence of non-confounded HIV-associated neurocognitive impairment in the context of plasma HIV RNA suppression. J Neurovirol. 2011;17: 176–183.
- Heaton R. Demographic influences and use of demograph-ically corrected norms in neuropsychological assessment. In: Grant I, Adams KM, eds. Neuropsychological Assess-ment of Neuro psychiatric and Neuronal Disorders. 3rd ed. New York: Oxford University Press; 2009:127–155.
- Cysique LA, Maruff P, Darby D, Brew BJ. The assess-ment of cognitive function in advanced HIV-1 infection and AIDS dementia complex using a new computerised cognitive test battery. Arch Clin Neuropsychol. 2006;21: 185–194.
- Antinori A, Arendt G, Becker JT, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology. 2007;69:1789–1799.
- Mills EJ, Nachega JB, Buchan I, et al. Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. JAMA. 2006;296:679–690.
- Hinkin CH, Castellon SA, Durvasula RS, et al. Medica-tion adherence among HIV+ adults. Effects of cogni-tive dysfunction and regimen complexity. Neurology. 2002;59:1944–1950.